5.88

8.29% 0.45

Myriad Genetics Inc (MYGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MYGN? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$5.43

Offen:

$5.44

24-Stunden-Volumen:

5.20M

Relative Volume:

3.31

Marktkapitalisierung:

$555.36M

Einnahmen:

$829.00M

Nettoeinkommen (Verlust:

$-399.90M

KGV:

-1.3624

EPS:

-4.3159

Netto-Cashflow:

$-23.20M

1W Leistung:

+29.52%

1M Leistung:

+52.73%

6M Leistung:

-9.26%

1J Leistung:

+10.32%

1-Tages-Spanne:

$5.34

$5.90

1-Wochen-Bereich:

$4.39

$5.90

52-Wochen-Spanne:

$3.53

$8.59

Myriad Genetics Inc Stock (MYGN) Company Profile

Firmenname

Myriad Genetics Inc

Sektor

Healthcare (1096)

Branche

Diagnostics & Research (48)

Telefon

801-584-3600

Adresse

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Mitarbeiter

2,700

Twitter

@myriadgenetics

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, A, NTRA

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MYGN Myriad Genetics Inc	5.88	512.85M	829.00M	-399.90M	-23.20M	-4.3159
TMO Thermo Fisher Scientific Inc	513.03	187.95B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	196.19	136.75B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	551.50	43.78B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	136.01	38.27B	7.23B	1.41B	1.09B	4.979
NTRA Natera Inc	261.91	37.34B	2.50B	-226.32M	71.51M	-1.6412

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-21	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2025-05-08	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-05-07	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-04-09	Herabstufung	Guggenheim	Buy → Neutral
2025-03-12	Hochstufung	Piper Sandler	Neutral → Overweight
2025-02-12	Eingeleitet	Craig Hallum	Buy
2024-12-10	Eingeleitet	UBS	Neutral
2024-12-09	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-19	Eingeleitet	Morgan Stanley	Equal-Weight
2024-08-28	Eingeleitet	Wells Fargo	Overweight
2024-06-27	Eingeleitet	Scotiabank	Sector Outperform
2024-06-03	Fortgesetzt	Jefferies	Underperform
2024-05-08	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-12-21	Fortgesetzt	Piper Sandler	Neutral
2023-12-19	Eingeleitet	Wells Fargo	Equal Weight
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-07-05	Fortgesetzt	JP Morgan	Underweight
2023-05-23	Hochstufung	Goldman	Sell → Buy
2023-01-18	Hochstufung	Raymond James	Mkt Perform → Outperform
2022-10-06	Eingeleitet	Stephens	Equal-Weight
2021-10-15	Fortgesetzt	Cowen	Market Perform
2021-06-15	Eingeleitet	Raymond James	Mkt Perform
2021-06-03	Eingeleitet	Goldman	Sell
2019-09-26	Herabstufung	BofA/Merrill	Neutral → Underperform
2019-08-14	Herabstufung	Piper Jaffray	Overweight → Neutral
2019-08-02	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-08-01	Hochstufung	Barclays	Underweight → Equal Weight
2019-07-29	Herabstufung	Needham	Strong Buy → Hold
2019-07-09	Herabstufung	Cowen	Outperform → Market Perform
2019-03-12	Bestätigt	Needham	Strong Buy
2019-01-03	Eingeleitet	Needham	Strong Buy
2018-11-30	Hochstufung	Goldman	Sell → Neutral
2018-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-07-11	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Eingeleitet	Goldman	Sell
2018-01-22	Bestätigt	Barclays	Equal Weight
2018-01-05	Eingeleitet	BTIG Research	Buy
2017-10-02	Fortgesetzt	Leerink Partners	Mkt Perform
2017-08-09	Bestätigt	Barclays	Equal Weight
2017-02-08	Hochstufung	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Eingeleitet	Deutsche Bank	Sell
2016-10-10	Herabstufung	Ladenburg Thalmann	Neutral → Sell

Alle ansehen

Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten

10:01 AM

Enterprise value to revenue forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Myriad Genetics, Inc. – LS:897518 - TradingView

Jun 26, 2026

MYGN Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Myriad Genetics, Inc. Actuals & Estimates (FWB:MYD) - TradingView

Jun 26, 2026

Jun 25, 2026

Myriad Genetics clears analyst hurdle, shares steady on NASDAQ - Ad-hoc-news.de

Jun 25, 2026

MYD Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today - Yahoo Finance

Jun 24, 2026

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication - Sahm

Jun 24, 2026

Jun 23, 2026

Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake - Stock Titan

Jun 23, 2026

Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Australia

Jun 23, 2026

Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Australia

Jun 23, 2026

MYGN PE Ratio & Valuation, Is MYGN Overvalued - Intellectia AI

Jun 23, 2026

Myriad Genetics expands cancer detection test availability - Investing.com

Jun 23, 2026

Myriad Genetics director Daniel Skovronsky resigns from board By Investing.com - Investing.com Australia

Jun 23, 2026

Myriad Genetics director Daniel Skovronsky resigns from board - Investing.com UK

Jun 23, 2026

MYRIAD GENETICS, INC. 8-K Filing: Key Company Information and SEC Compliance Details for June 2026 - Minichart

Jun 23, 2026

Myriad widens cancer test access as breast study bolsters its case - Stock Titan

Jun 23, 2026

Board member Skovronsky exits Myriad Genetics (NASDAQ: MYGN) - Stock Titan

Jun 23, 2026